Solutions for CAR-T Cell Therapy, Adoptive Cell Therapy Discovery and Development
Chimeric antigen receptor T cell-based therapy, using engineered T cells to fight cancer, is a transformative technology like gene therapy or regenerative medicine that may forever change the landscape of medicine. CAR-T cell-based therapy uses immune cells – either the patient’s own (autologous) or from a donor (allogeneic) – that have been genetically transformed and are then infused into the patient to bind to cancer cells and destroy them.
At Sartorius, we know every detail of the CAR-T development workflow counts. We believe your ambition is to achieve the highest quality results every day: results that are reproducible, publishable, and actionable, resulting in breakthrough therapy. That’s why we strive to provide innovative solutions, from biomarker identification to production. We want to help you develop the safest CAR-T product, with the highest levels of productivity. Our goal is to support you at every step of the translational research process, and ensure that you never compromise your ambition.
Recent FDA & EMA approvals of CAR-T cell therapies (Kymriah®, Yescarta®) have revolutionized the available therapeutic landscape and given new hope to patients, the medical field, and the research community. To achieve the necessary efficacy and safety for approval of a CAR-T cell therapy, researchers must understand their model systems, identify potential therapeutic targets, and evaluate corresponding hits at an unprecedented level, as early as possible.
The discovery and development process has many steps during which results must remain uncompromised, such as:
- Isolation of tumor infiltrating lymphocytes (TILs) or circulating T cells
- Early in vitro assays deploying specific tumor cell models and understanding immune cell activation
- CAR-T vector choice for viral gene transfer
- Imaging and flow cytometry to assess biological responses
- In vivo studies in animals
- Clinical trials involving human subjects
It starts with basic foundational elements like proper pipetting and liquid-handling technique, aseptic cell culture handling, expansion under optimal conditions, and confidence that cultures are free from contaminating agents such as mycoplasma. False positive and false negative results, as well as random or uncontrollable artifacts, can significantly decelerate the discovery and development process, potentially hindering novel insights. Your work requires equipment, technology, and assays specifically developed to deliver safety, speed, and productivity.
Sartorius has developed comprehensive and complementary solutions to help you trust your therapy. Read below to learn what solutions are right for your CAR-T therapy discovery and development efforts.
How Sartorius accelerates and provides confidence in your CAR-T discovery & development
- Safety: in-depth sample analysis, fast and precise viral vector quantification, rapid detection of contaminants
- Speed: rapid sample acquisition, no-wash assays, optimized reagents, advanced analysis software
- Productivity: multiparametric measurement of T-cell dependent cytotoxicity, CAR-T cell phenotype, CAR transduction and activation
- Biologically relevant results: extension of 2D assays to 3D cultures, assays for both adherent (dissociated solid tumor cells) and non-adherent cell lines
- Cell characterization & QA/QC: continuous phenotypic & functional analysis over time, under aseptic conditions
NEW WEBINAR RECORDING
Gaining Critical Product Characterization Insights for CAR T Cell Therapy Research
Join a roundtable webinar reviewing the state-of-the-art in cell analysis and its specific utility in the CAR T cell therapy space as it seeks to advance beyond haematological malignancies and into the solid tumor space.
CAR T-cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunotherapy
Register now to watch a panel of experts discuss the design, development, and success of CAR T-cell therapy and bispecific antibodies and the potential these therapeutics hold in the fight against various tumor types.
Discover Our Solutions
By maximizing the probability of success and minimizing failure rates throughout the R&D process, we ultimately help decrease overall cost and time from bench to bedside.
Whether considering autologous or allogeneic CAR-T therapies, numerous challenges present themselves, among them target antigen selection, on-/off-target screening, CAR delivery, appropriate tumor cell lines, animal models and clinical relevance, tumor heterogeneity, immune escape, expansion and persistence, neurotoxicity, and cytokine release syndrome.
To address this high degree of complexity and the inherently ever-evolving nature of cancer biology, Sartorius supports and enables scientists in their quest to develop the next generation of CAR-T therapies by providing solutions to increase speed and throughput, decrease costs, and allow validation of results via multiparametric methods. We improve product safety and increase trust in the global body of knowledge by providing scientific instrumentation (e.g. flow cytometers, imagers) and equipment and consumables (pipettes & tips, detection kits, and more) of the highest quality and peak functionality.
Discover how Sartorius can help you trust your therapy and have confidence throughout your CAR-T development process with a portfolio that ranges from basic foundational tools, such as pipettes and mycoplasma detection kits, to elegant and intricate technologies, such as real-time non-perturbing cell analysis, flow-based CAR-T vector characterization requiring minimal sample volumes, and GMP-compliant cell expansion platforms.